Kelley Anne Saia, MD
Associate Professor, Obstetrics & Gynecology
Biography
Expertise includes: Treatment of substance use disorders in pregnancy and post-pregnancy, including opioid, alcohol, stimulant and marijuana use disorders; Trauma-informed care for pregnant persons with substance use disorder
Education
- University of Vermont, MD
- Georgetown University, BSN
- Hobart and William Smith Colleges, BA
Publications
- Published on 7/1/2024
Khazanchi R, Wachman EM, Schiff DM, Modest A, Saia KA, Hsu HE. Mandatory Child Protective Services Reporting for Substance-Exposed Newborns and Peripartum Outcomes: A Difference-in-Differences Analysis. JAMA Pediatr. 2024 Jul 01; 178(7):719-722. PMID: 38709513.
Read at: PubMed - Published on 5/21/2024
Mantri S, Cheng AC, Saia K, Shrestha H, Amgott R, Bressler J, Werler MM, Carter G, Jones HE, Wachman EM. Neurobehavioral outcomes of infants exposed to buprenorphine-naloxone compared with naltrexone during pregnancy. Early Hum Dev. 2024 Jul; 194:106051. PMID: 38815498.
Read at: PubMed - Published on 2/14/2024
Wachman EM, Saia K, Bressler J, Werler M, Carter G, Jones HE. Case Series of Individuals Treated With Naltrexone During Pregnancy for Opioid and/or Alcohol Use Disorder. J Addict Med. 2024 May-Jun 01; 18(3):288-292. PMID: 38354121.
Read at: PubMed - Published on 10/1/2023
Harris M, Schiff DM, Saia K, Muftu S, Standish KR, Wachman EM. Academy of Breastfeeding Medicine Clinical Protocol #21: Breastfeeding in the Setting of Substance Use and Substance Use Disorder (Revised 2023). Breastfeed Med. 2023 Oct; 18(10):715-733. PMID: 37856658.
Read at: PubMed - Published on 9/20/2023
Deflorimonte C, Glissendorf V, Hofer J, Cai A, Iannella N, Boateng JO, Carter G, Saia KA, Jones HE, Wachman EM. National Provider Survey: Use of Naltrexone for Pregnant Individuals with Substance Use Disorders. J Addict Med. 2023 Nov-Dec 01; 17(6):736-738. PMID: 37934548.
Read at: PubMed - Published on 9/20/2023
Deflorimonte C, Glissendorf V, Hofer J, Cai A, Iannella N, Boateng JO, Carter G, Saia KA, Jones HE, Wachman EM. National Provider Survey: Use of Naltrexone for Pregnant Individuals with Substance Use Disorders. J Addict Med. 2023 Sep 20. PMID: 37729010.
Read at: PubMed - Published on 8/22/2023
Valentine SE, Godfrey LB, Gellatly R, Paul E, Clark C, Giovannini K, Saia KA, Nillni YI. Supporting the implementation of written exposure therapy for posttraumatic stress disorder in an obstetrics-substance use disorder clinic in the Northeastern United States. SSM Ment Health. 2023 Dec 15; 4. PMID: 38645900.
Read at: PubMed - Published on 6/3/2023
Wanar A, Saia K, Field TA. Accelerated Fentanyl Metabolism During Pregnancy and Impact on Prenatal Drug Testing. Matern Child Health J. 2023 Nov; 27(11):1944-1948. PMID: 37269392.
Read at: PubMed - Published on 5/19/2023
Holland E, Gibbs L, Spence NZ, Young M, Werler MM, Guang Z, Saia K, Bateman BT, Achu R, Wachman EM. A comparison of postpartum opioid consumption and opioid discharge prescriptions among opioid-naïve patients and those with opioid use disorder. Am J Obstet Gynecol MFM. 2023 Aug; 5(8):101025. PMID: 37211090.
Read at: PubMed - Published on 1/9/2023
Laks J, Walley AY, Bagley SM, Barber CM, Gaeta JM, Neville LA, Peterkin AF, Rosenthal E, Saia KA, Weinstein ZM, Harris MTH. Developing a Women's Health track within addiction medicine fellowship: reflections and inspirations. Addict Sci Clin Pract. 2023 Jan 09; 18(1):3. PMID: 36617557.
Read at: PubMed
View 31 more publications: View full profile at BUMC